Accuray Inc. Introduces the CyberKnife(R) VSI(TM) System New Capabilities Extend CyberKnife Treatment Options to Include Robotic IMRT

SUNNYVALE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Accuray Incorporated , a global leader in the field of radiosurgery, announced today the introduction of the CyberKnife((R)) VSI(TM) System, the latest addition to the CyberKnife product family. The new CyberKnife VSI, which stands for versatile, simple and intelligent, is designed to broaden physicians’ range of options from radiosurgery to also include conventionally fractionated Robotic IMRT. This enables them to customize their care around the unique needs of each patient, thereby expanding the population of patients that can benefit from the System’s unparalleled precision.

CyberKnife VSI System features product enhancements including a world-class 1,000 MU/minute X-band linear accelerator, advanced visualization capabilities, automated segmentation capabilities and logical workflow designed to enhance the physician and patient experience.

Clinical Flexibility

From a radiosurgical approach to a conventionally fractionated Robotic IMRT(TM) approach, the CyberKnife VSI System provides the clinician the flexibility to choose the best course of care based on individual patient needs. The CyberKnife VSI System supports this full spectrum of fractionation schemes by enabling simple and convenient treatments that can be completed in routine clinical practice. Treatment times are expected to be comparable to IMRT delivered using a conventional linear accelerator.

For the treatment of lung tumors, the CyberKnife VSI System can intelligently track respiratory motion in real-time and automatically adapt to changes in the patient’s breathing pattern. For prostate cancer, the CyberKnife VSI System can address the unique challenges of random and excessive target motion by using intelligent and adaptive image guidance. These capabilities ultimately result in minimized dose to surrounding healthy tissue and critical structures, minimizing treatment complications and side effects.

“There is a tremendous need for the capabilities built into the new CyberKnife VSI,” said Dwight Heron, M.D., chairman of the Department of Radiation Oncology at UPMC Shadyside. “Depending on each individual patient’s case, we will now be able to better tailor care so that the right amount of radiation is delivered to the right place in the right time frame for each patient, all with the same accuracy for which the CyberKnife is known.”

Additionally, a high-resolution image of the CyberKnife VSI System can be downloaded from Accuray’s virtual press kit: www.accuray.com/media/virtualpresskit.

About the CyberKnife((R)) Robotic Radiosurgery System

Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 180 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

CONTACT: Stephanie Tomei, Senior Manager, Marketing Communications,
+1-408-789-4234, stomei@accuray.com; or Brianne Donahue, Schwartz
Communications, +1-415-817-2545, accuray@schwartz-pr.com

Web site: http://www.accuray.com/

MORE ON THIS TOPIC